Diagnostic Imaging's Weekly Scan: Nov. 27, 2020
Low-dose CT for lung cancer screening offers significant benefits for detection and follow-up, but utilization, to date, has been low. Debra S. Dyer, M.D., chair of the American College of Radiology's Lung Cancer Screening 2.0 Committee discusses what the screening provides and the challenges to more widespread implementation.
Welcome to Diagnostic Imaging. I’m senior editor, Whitney Palmer
It’s Lung Cancer Awareness month, and one of the biggest advancements in the detection of the disease in recent years has been low-dose CT for screening. Not only does this technique offer a way to pinpoint whether a patient has lung cancer without exposing him or her to high levels of radiation, but it also provides a safe way to conduct multiple follow-up scans, as needed.
However, to date, utilization of this low-dose method has fallen well below expectations and hopes. With only 4.5 percent to 5 percent of eligible patients actually getting scanned, there’s a lot of room for improvement. This week, Diagnostic Imaging spoke with Dr. Debra Dyer, chair of the American College of Radiology’s Lung Cancer Screening 2.0 Committee about the benefits of low-dose CT, the challenges that exist to wider adoption and implementation, and what providers and facilities can do to increase screening rates.
Here’s what she had to say.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
